Brief: Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism
09/12/2025 13:02
Dec 9 (Reuters) - Celldex Therapeutics Inc CLDX.O: CELLDEX INITIATES GLOBAL REGISTRATIONAL PHASE 3 PROGRAM OF BARZOLVOLIMAB IN COLD URTICARIA AND SYMPTOMATIC DERMOGRAPHISM CELLDEX THERAPEUTICS INC - DATA FROM OPEN LABEL EXTENSION EXPECTED IN Q1 2026 Source text: ID:nGNX62mB5j Further company coverage: CLDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials